

NDA 215358/S-004

**SUPPLEMENT APPROVAL/  
FULFILLMENT OF POSTMARKETING  
REQUIREMENTS**

Novartis Pharmaceuticals Corporation  
Attention: Tina Lertharakul, PharmD  
Senior Global Program Regulatory Manager  
One Health Plaza  
East Hanover, NJ 07936

Dear Dr. Lertharakul:

Please refer to your supplemental new drug application (sNDA) dated May 10, 2023, received May 10, 2023, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for SCEMBLIX (asciminib) tablets.

This Prior Approval supplemental new drug application (sNDA) provides for updates to the potential drug interaction between asciminib and substrates of OATP1B and/or BCRP in Sections 7 and 12 of the United States Prescribing Information (USPI).

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert), with the addition of any labeling

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **FULFILLMENT OF POSTMARKETING REQUIREMENTS**

We have received your submission dated November 30, 2022, containing the final reports for the following postmarketing requirements listed in the October 29, 2021, approval letter for NDA 215358/Original 1.

- 4161-3 Conduct a physiologically based pharmacokinetic study sufficient to evaluate the effect of repeated doses of asciminib on the single dose pharmacokinetics of a breast cancer resistance protein (BCRP) substrate to address the potential for excessive drug toxicity and determine appropriate dosage recommendations when asciminib is administered concomitantly with BCRP substrates. Design and conduct the study in accordance with the FDA Guidances for Industry titled “Clinical Drug

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions” and/or “Physiologically Based Pharmacokinetic Analyses — Format and Content”.

- 4161-4 Conduct a physiologically based pharmacokinetic study sufficient to evaluate the effect of repeated doses of asciminib on the single dose pharmacokinetics of an organic anion transporting polypeptide (OATP1B) substrate to address the potential for excessive drug toxicity and determine appropriate dosage recommendations when asciminib is administered concomitantly with OATP1B1/3 substrates. Design and conduct the assessment in accordance with the FDA Guidances for Industry titled “Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions” and/or “Physiologically Based Pharmacokinetic Analyses — Format and Content”.

We have reviewed your submission and conclude that the above requirements were fulfilled.

We remind you that there is a postmarketing requirement and postmarketing commitments listed in the October 29, 2021, approval letter that are still open.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rachel McMullen, Senior Regulatory Project Manager, at (240) 402-4574.

Sincerely,

*{See appended electronic signature page}*

Kelly Norsworthy, MD  
Deputy Division Director  
Division of Hematologic Malignancies I  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

KELLY J NORSWORTHY  
11/08/2023 04:19:40 PM